Aperture Therapeutics Announces Development Candidate Targeting CD33 to Restore Microglial Homeostasis in FTD and ALS
SAN CARLOS, Calif., Nov. 19, 2025 /PRNewswire/ — Aperture Therapeutics, a biotechnology company pioneering next-generation precision medicines for neurodegenerative diseases,…
